A Single Center, Open, Randomized, Placebo-controlled Study Investigating the Safety of Administration of Ilomedin in Addition to Standard Treatment in Patients Having Undergone Primary Percutaneous Coronary Intervention (PCI).
Phase of Trial: Phase I/II
Latest Information Update: 16 Feb 2013
At a glance
- Drugs Iloprost (Primary)
- Indications Coronary artery disease; Embolism and thrombosis
- Focus Adverse reactions
- Sponsors Thrombologic
- 01 Jun 2011 Status changed from recruiting to completed added as reported by ClinicalTrials.gov.
- 01 Jun 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
- 08 Oct 2010 Actual initiation date (Sep 2010) added as reported by ClinicalTrials.gov.